Functional assays for BRCA1 and BRCA2

International Journal of Biochemistry and Cell Biology

Volumn 39, Issue 2, 2007, Pages 298-310

  Carvalho, Marcelo A ^a,b   Couch, Fergus J ^c   Monteiro, Alvaro N A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b INSTITUTO FEDERAL DE EDUCAÇÃO   (Brazil)

^c MAYO CLINIC   (United States)

Author keywords

BRCA1; BRCA2; Cancer risk; Functional assays; Unclassified variants

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN MSH2; UBIQUITIN PROTEIN LIGASE E3;

BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CENTROSOME; CROSS LINKING; ENZYME ACTIVITY; FRAMESHIFT MUTATION; GENE AMPLIFICATION; GENE DELETION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SCREENING; HOMOLOGOUS RECOMBINATION; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; PHENOTYPE; PROTEIN DETERMINATION; PROTEIN FUNCTION; RADIOSENSITIVITY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL; TRANSCRIPTION INITIATION;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC SCREENING; HUMANS; MUTATION, MISSENSE; RISK; SENSITIVITY AND SPECIFICITY;

EID: 33845187523     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2006.08.002     Document Type: Review

References (92)

1. Abbott D.W., Thompson M.E., Robinson-Benion C., Tomlinson G., Jensen R.A., and Holt J.T. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J. Biol. Chem. 274 (1999) 18808-18812
2. Agata S., la Palma M., Callegaro M., Scaini M.C., Menin C., Ghiotto C., et al. Large genomic deletions inactivate the BRCA2 gene in breast cancer families. J. Med. Genet. 42 (2005) e64
3. Baer R., and Ludwig T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr. Opin. Genet. Dev. 12 (2002) 86-91
4. Bertwistle D., Swift S., Marston N.J., Jackson L.E., Crossland S., Crompton M.R., et al. Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res. 57 (1997) 5485-5488
5. Bochar D.A., Wang L., Beniya H., Kinev A., Xue Y., Lane W.S., et al. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 102 (2000) 257-265
6. Brzovic P.S., Keeffe J.R., Nishikawa H., Miyamoto K., Fox III D., Fukuda M., et al. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 5646-5651
7. Brzovic P.S., Meza J., King M.C., and Klevit R.E. The cancer-predisposing mutation C61G disrupts homodimer formation in the NH2-terminal BRCA1 RING finger domain. J. Biol. Chem. 273 (1998) 7795-7799
8. Cantor S.B., Bell D.W., Ganesan S., Kass E.M., Drapkin R., Grossman S., et al. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105 (2001) 149-160
9. Carvalho M.A., Billack B., Chan E., Worley T., Cayanan C., and Monteiro A.N. Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation. Cancer Biol. Ther. 1 (2002) 502-508
10. Chen P.L., Chen C.F., Chen Y., Xiao J., Sharp Z.D., and Lee W.H. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 5287-5292
11. Chen Y., Farmer A.A., Chen C.F., Jones D.C., Chen P.L., and Lee W.H. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res. 56 (1996) 3168-3172 (published erratum appears in Cancer Res. 1996, 56(17), 4074)
12. Chen A., Kleiman F.E., Manley J.L., Ouchi T., and Pan Z.Q. Autoubiquitination of the BRCA1 × BARD1 RING ubiquitin ligase. J. Biol. Chem. 277 (2002) 22085-22092
13. Cortez D., Wang Y., Qin J., and Elledge S.J. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286 (1999) 1162-1166 [see comments]
14. Couch F.J., and Weber B.L. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum. Mutat. 8 (1996) 8-18
15. Coyne R.S., McDonald H.B., Edgemon K., and Brody L.C. Functional characterization of BRCA1 sequence variants using a yeast small colony phenotype assay. Cancer Biol. Ther. 3 (2004) 453-457
16. Daniels M.J., Wang Y., Lee M., and Venkitaraman A.R. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 306 (2004) 876-879
17. Davies A.A., Masson J.Y., McIlwraith M.J., Stasiak A.Z., Stasiak A., Venkitaraman A.R., et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol. Cell 7 (2001) 273-282
18. Estojak J., Brent R., and Golemis E.A. Correlation of two-hybrid affinity data with in vitro measurements. Mol. Cell Biol. 15 (1995) 5820-5829
19. Foray N., Randrianarison V., Marot D., Perricaudet M., Lenoir G., and Feunteun J. Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2. Oncogene 18 (1999) 7334-7342
20. Ford D., Easton D.F., Stratton M., Narod S., Goldgar D., Devilee P., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62 (1998) 676-689
21. Frank T.S., Deffenbaugh A.M., Reid J.E., Hulick M., Ward B.E., Lingenfelter B., et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J. Clin. Oncol. 20 (2002) 1480-1490
22. Frank T.S., Manley S.A., Olopade O.I., Cummings S., Garber J.E., Bernhardt B., et al. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. J. Clin. Oncol. 16 (1998) 2417-2425
23. Friedman L.S., Ostermeyer E.A., Szabo C.I., Dowd P., Lynch E.D., Rowell S.E., et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat. Genet. 8 (1994) 399-404
24. Futreal P.A., Liu Q., Shattuck-Eidens D., Cochran C., Harshman K., Tavtigian S., et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266 (1994) 120-122
25. Galkin V.E., Esashi F., Yu X., Yang S., West S.C., and Egelman E.H. BRCA2 BRC motifs bind RAD51-DNA filaments. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 8537-8542
26. Gill G., Sadowski I., and Ptashne M. Mutations that increase the activity of a transcriptional activator in yeast and mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 2127-2131
27. Goldgar D.E., Easton D.F., Deffenbaugh A.M., Monteiro A.N., Tavtigian S.V., and Couch F.J. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am. J. Hum. Genet. 75 (2004) 535-544
28. Hashizume R., Fukuda M., Maeda I., Nishikawa H., Oyake D., Yabuki Y., et al. The ring heterodimer brca1-bard1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem. 276 (2001) 14537-14540
29. Hayes F., Cayanan C., Barilla D., and Monteiro A.N. Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation. Cancer Res. 60 (2000) 2411-2418
30. Hogervorst F.B., Cornelis R.S., Bout M., van Vliet M., Oosterwijk J.C., Olmer R., et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat. Genet. 10 (1995) 208-212
31. Hu Y.F., Hao Z.L., and Li R. Chromatin remodeling and activation of chromosomal DNA replication by an acidic transcriptional activation domain from BRCA1. Genes Dev. 13 (1999) 637-642
32. Humphrey J.S., Salim A., Erdos M.R., Collins F.S., Brody L.C., and Klausner R.D. Human BRCA1 inhibits growth in yeast: Potential use in diagnostic testing. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 5820-5825
33. Kleiman F.E., and Manley J.L. Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50. Science 285 (1999) 1576-1579
34. Kraakman-van der Z.M., Overkamp W.J., van Lange R.E., Essers J., van Duijn-Goedhart A., Wiggers I., et al. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol. Cell Biol. 22 (2002) 669-679
35. Lancaster J.M., Wooster R., Mangion J., Phelan C.M., Cochran C., Gumbs C., et al. BRCA2 mutations in primary breast and ovarian cancers. Nat. Genet. 13 (1996) 238-240
36. Lane T.F. BRCA1 and transcription. Cancer Biol. Ther. 3 (2004) 528-533
37. Li S., Ting N.S., Zheng L., Chen P.L., Ziv Y., Shiloh Y., et al. Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature 406 (2000) 210-215
38. Lorick K.L., Jensen J.P., Fang S., Ong A.M., Hatakeyama S., and Weissman A.M. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 11364-11369
39. Martin S.T., Matsubayashi H., Rogers C.D., Philips J., Couch F.J., Brune K., et al. Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene 24 (2005) 3652-3656
40. Marx J. Zeroing in on individual cancer risk. Science 253 (1991) 612-616
41. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (1994) 66-71
42. Milner J., Ponder B., Hughes-Davies L., Seltmann M., and Kouzarides T. Transcriptional activation functions in BRCA2. Nature 386 (1997) 772-773
43. Mirkovic N., Marti-Renom M.A., Weber B.L., Sali A., and Monteiro A.N. Structure-based assessment of missense mutations in human BRCA1: Implications for breast and ovarian cancer predisposition. Cancer Res. 64 (2004) 3790-3797
44. Monteiro A.N. BRCA1: Exploring the links to transcription. Trends Biochem. Sci. 25 (2000) 469-474
45. Monteiro A.N., August A., and Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 13595-13599
46. Monteiro A.N., August A., and Hanafusa H. Common BRCA1 variants and transcriptional activation [letter]. Am. J. Hum. Genet. 61 (1997) 761-762
47. Monteiro A.N., and Couch F.J. Cancer risk assessment at the atomic level. Cancer Res. 66 (2006) 1897-1899
48. Monteiro A.N., and Humphrey J.S. Yeast-based assays for detection and characterization of mutations in BRCA1. Breast Dis. 10 (1998) 61-70
49. Morris J.R., Pangon L., Boutell C., Katagiri T., Keep N.H., and Solomon E. Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Hum. Mol. Genet. 15 (2006) 599-606
50. Moynahan M.E., Chiu J.W., Koller B.H., and Jasin M. Brca1 controls homology-directed DNA repair. Mol. Cell 4 (1999) 511-518
51. Moynahan M.E., Cui T.Y., and Jasin M. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a brca1 mutation. Cancer Res. 61 (2001) 4842-4850
52. Moynahan M.E., Pierce A.J., and Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol. Cell 7 (2001) 263-272
53. Narod S.A., and Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 4 (2004) 665-676
54. Narod S.A., and Offit K. Prevention and management of hereditary breast cancer. J. Clin. Oncol. 23 (2005) 1656-1663
55. Neish A.S., Anderson S.F., Schlegel B.P., Wei W., and Parvin J.D. Factors associated with the mammalian RNA polymerase II holoenzyme. Nucleic Acids Res. 26 (1998) 847-853
56. Newman B., Austin M.A., Lee M., and King M.C. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 3044-3048
57. Phelan C.M., Dapic V., Tice B., Favis R., Kwan E., Barany F., et al. Classification of BRCA1 missense variants of unknown clinical significance. J. Med. Genet. 42 (2005) 138-146
58. Puget N., Stoppa-Lyonnet D., Sinilnikova O.M., Pages S., Lynch H.T., Lenoir G.M., et al. Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer Res. 59 (1999) 455-461
59. Ries L.A.G., Einser M.P., Rosary C.L., Hankey B.F., Miller B.A., Clegg L., et al. SEER cancer statistics review 1975-2002 (2005), National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2002/ National Cancer Institute [On-line]. Available
60. Ruffner H., Joazeiro C.A., Hemmati D., Hunter T., and Verma I.M. Cancer-predisposing mutations within the RING domain of BRCA1: Loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 5134-5139
61. Scully R., Anderson S.F., Chao D.M., Wei W., Ye L., Young R.A., et al. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 5605-5610
62. Scully R., Chen J., Ochs R.L., Keegan K., Hoekstra M., Feunteun J., et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90 (1997) 425-435
63. Scully R., Ganesan S., Vlasakova K., Chen J., Socolovsky M., and Livingston D.M. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol. Cell 4 (1999) 1093-1099
64. Scully R., and Livingston D. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408 (2000) 429-432
65. Scully R., Xie A., and Nagaraju G. Molecular functions of BRCA1 in the DNA damage response. Cancer Biol. Ther. 3 (2004) 521-527
66. Shen S.X., Weaver Z., Xu X., Li C., Weinstein M., Chen L., et al. A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 17 (1998) 3115-3124
67. Spain B.H., Larson C.J., Shihabuddin L.S., Gage F.H., and Verma I.M. Truncated BRCA2 is cytoplasmic: Implications for cancer-linked mutations. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 13920-13925
68. Starita L.M., Horwitz A.A., Keogh M.C., Ishioka C., Parvin J.D., and Chiba N. BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II. J. Biol. Chem. 280 (2005) 24498-24505
69. Starita L.M., Machida Y., Sankaran S., Elias J.E., Griffin K., Schlegel B.P., et al. BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. Mol. Cell Biol. 24 (2004) 8457-8466
70. Struewing J.P., Abeliovich D., Peretz T., Avishai N., Kaback M.M., Collins F.S., et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat. Genet. 11 (1995) 198-200 [see comments] [published erratum appears in Nat Genet 1996; 12(1), 110]
71. Szabo C.I., Worley T., and Monteiro A.N. Understanding germ-line mutations in BRCA1. Cancer Biol. Ther. 3 (2004) 515-520
72. Tavtigian S.V., Simard J., Rommens J., Couch F., Shattuck-Eidens D., Neuhausen S., et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat. Genet. 12 (1996) 333-337
73. Thomas J.E., Smith M., Tonkinson J.L., Rubinfeld B., and Polakis P. Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage. Cell Growth Differ. 8 (1997) 801-809
74. Tutt A., Gabriel A., Bertwistle D., Connor F., Paterson H., Peacock J., et al. Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr. Biol. 9 (1999) 1107-1110
75. Unger M.A., Nathanson K.L., Calzone K., Antin-Ozerkis D., Shih H.A., Martin A.M., et al. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am. J. Hum. Genet. 67 (2000) 841-850
76. Vallon-Christersson J., Cayanan C., Haraldsson K., Loman N., Bergthorsson J.T., Brondum-Nielsen K., et al. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum. Mol. Genet. 10 (2001) 353-360
77. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108 (2002) 171-182
78. Wilson C.A., Ramos L., Villasenor M.R., Anders K.H., Press M.F., Clarke K., et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat. Genet. 21 (1999) 236-240
79. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378 (1995) 789-792
80. Wooster R., and Weber B.L. Breast and ovarian cancer. N. Engl. J. Med. 348 (2003) 2339-2347
81. Worley T., Vallon-Christersson J., Billack B., Borg A., and Monteiro A.N. A naturally occurring allele of brca1 coding for a temperature-sensitive mutant protein. Cancer Biol. Ther. 1 (2002) 497-501
82. Wu K., Hinson S.R., Ohashi A., Farrugia D., Wendt P., Tavtigian S.V., et al. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res. 65 (2005) 417-426
83. Wu L.C., Wang Z.W., Tsan J.T., Spillman M.A., Phung A., Xu X.L., et al. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat. Genet. 14 (1996) 430-440
84. Wu-Baer F., and Baer R. Tumour suppressors (communication arising): effect of DNA damage on a BRCA1 complex. Nature 414 (2001) 36
85. Wu-Baer F., Lagrazon K., Yuan W., and Baer R. The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. J. Biol. Chem. 278 (2003) 34743-34746
86. Xia F., Taghian D.G., DeFrank J.S., Zeng Z.C., Willers H., Iliakis G., et al. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 8644-8649
87. Xia Y., Pao G.M., Chen H.W., Verma I.M., and Hunter T. Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein. J. Biol. Chem. 278 (2003) 5255-5263
88. Yu V.P., Koehler M., Steinlein C., Schmid M., Hanakahi L.A., van Gool A.J., et al. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev. 14 (2000) 1400-1406
89. Zhang J., and Powell S.N. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol. Cancer Res. 3 (2005) 531-539
90. Zhong Q., Boyer T.G., Chen P.L., and Lee W.H. Deficient nonhomologous end-joining activity in cell-free extracts from Brca1-null fibroblasts. Cancer Res. 62 (2002) 3966-3970
91. Zhong Q., Chen C.F., Chen P.L., and Lee W.H. BRCA1 facilitates microhomology-mediated end joining of DNA double strand breaks. J. Biol. Chem. 277 (2002) 28641-28647
92. Zhou B.B., and Elledge S.J. The DNA damage response: Putting checkpoints in perspective. Nature 408 (2000) 433-439